Bristol Myers Squibb (BMS) will collaborate with Temedica, a digital health and health insights company, to develop an app for patients living with psoriasis. The app will be available to all psoriasis patients in Germany.

The interactive app will allow psoriasis patients to better understand their individual disease course and gain further understanding into potential influencing factors. The app can give patients a tailored user experience, with motivation and encouragement towards recommended lifestyle changes to help improve their condition.

Patients will be able to share their health and disease progression data with their healthcare providers through an export function integrated into the app. This will allow physicians to monitor and adjust their patients' therapy accordingly.

Gloria Seibert, founder and CEO at Temedica, said: “Psoriasis affects each patient differently, so we integrate the advice of patients as well as healthcare professionals in designing a digital companion that meets the patients’ needs.”

Temedica apps are characterised by combining medical expertise with a spotlight on patient safety and improved therapy outcomes.

Psoriasis affects around 2 million people in Germany and is one of the most common chronic inflammatory skin diseases. Currently, no cure exists for the condition, and patients are left to deal with the difficulties of trying to manage their symptoms through the use of various prescriptions.